Pharmaceutical company partnerships and milestone and royalty income following early-stage development
First written in FY2023. 4 of 8 entries say "Restated". Latest entry: FY2027-H1.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「The Company holds the exclusive development and commercialization rights for TMS-007 in Japan and the right to receive milestone payments and royalties for development and sales worldwide excluding Japan.」
The Company reaffirmed its partnership-based business model for TMS-007. - 2026-04-24First statedGeneral Meetings of Shareholders
「We are validating the market potential and commercial viability of our various pipelines, organizing the optimal methods for commercialization, and have also begun engaging with external parties regarding some of the pipelines.」
The theme of validating the market potential and commercial viability of existing pipelines, organizing commercialization methods, and beginning external engagement for some pipelines was first presented specifically in the timely disclosure. - FY2026-H1RestatedAnnual report
「The Company holds from CORXEL the exclusive development and commercialization rights for TMS-007 in Japan and the right to receive milestone payments and royalties for development and sales worldwide excluding Japan.」
The Company reaffirmed its partnership-based model under which CORXEL leads global development and the Company holds Japanese rights and receives milestones and royalties outside Japan. - FY2025ReframedAnnual report
「Under the Company’s basic business model, it conducts activities from the research stage through the early clinical stage, then partners with pharmaceutical companies in Japan and overseas from the late clinical stage onward, granting development, manufacturing and commercialization rights and receiving milestone payments, royalties and other income. Depending on the disease area, the Company also considers conducting late-stage clinical development, obtaining approval and even sales itself.」
In addition to its traditional model of partnering from the late clinical stage, the Company may handle late-stage trials, approval and sales itself in certain disease areas. - FY2025-H1RestatedAnnual report
「The Company currently holds the exclusive development and commercialization rights for TMS-007 in Japan and the right to receive milestone payments and royalties from JIXING for development and sales worldwide excluding Japan.」
The Company reaffirmed its exclusive Japanese rights and entitlement to milestone and royalty payments outside Japan while supporting JIXING-led preparations for the next trial. - FY2025-Q1RestatedAnnual report
「The Company currently holds the exclusive development and commercialization rights for TMS-007 in Japan and the right to receive milestone payments and royalties from JIXING for development and sales worldwide excluding Japan.」
The Company reaffirmed that it holds exclusive development and commercialization rights in Japan and rights to milestone and royalty payments for the rest of the world through its partnership with JIXING. - FY2024-Q3AdvancedAnnual report
「JIXING HK will assume Biogen’s position under the option agreement and acquire worldwide intellectual property rights to the SMTP compounds, including TMS-007 and TMS-008. The Company and JIXING HK will establish a Joint Development and Commercialization Committee to exchange information and discuss TMS-007 development regularly.」
JIXING HK assumed Biogen’s contractual position and moved the relationship into a development and commercialization partnership. A joint committee was established for TMS-007, with a framework for the Company to receive milestones and royalties based on JIXING HK’s progress. - FY2023First statedAnnual report
「Under the Company’s basic business model, it conducts activities from the research stage through the early clinical stage, then partners with pharmaceutical companies in Japan and overseas from the late clinical stage onward, granting development, manufacturing and commercialization rights and receiving upfront development payments (milestones), royalties and other income from its partners.」
The Company’s business model is to conduct research and early clinical development internally and partner with pharmaceutical companies from the late clinical stage onward.